Breast lymph node assay

Zehentner BK, Dillon DC, Jiang Y, et al. Application of a muitigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 2002 48 1225-31. 

Hughes SJ, Xi L, Raja S, et al. A rapid, fully automated, molecular-based assay accurately analyzes sentinel lymph nodes for the presence of metastatic breast cancer. Ann Surg. 2006 243 389-398. 

Viale G, Dell Orto P, Biasi MO, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mam-maglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg. 2008 247 136-142. 

Mansel RE, Goyal A, Douglas-Jones A, et al. Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch BLN Assay in the operating room Results of the Gardiff study. Breast Cancer Res Treat. 2009 115 595-600. 

Martin Martinez MD, Veys I, Majjaj S, et al. Glinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes. Eur J Surg Oncol. 2009 35 387-392. 

In our experience (M7), 54% of primary breast carcinomas contain significant amounts of estrogen receptor protein compared with 42% of metastatic deposits. By far the most common sources of the metastases submitted for assay are skin, lymph nodes, and other nonvisceral soft tissue sources. The visceral metastases are the ones in which response to treatment is generally most important clinically, yet there is little information in the literature concerning the estrogen receptor protein status of visceral metastases. 

Another FDA apvproved diagnosis test is MammaPrint to assess the risk of breast tumor and this will help to decide the effectiveness of chemotherapy on the patients, (van t Veer et al, 2002) The assay uses the fresh tissue to study the Amsterdam 70-gene breast cancer gene signature by microarray analysis, (van t Veer et al, 2002) Readers interested in this test can also obtain more information about the MIND ACT trial (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemo Therapy) in the p>ap)er by Cardoso et al. (Cardoso et al, 2008)... 

---